Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 12, 2020 07:00 ET | Source: Cerecor Inc.

Cerecor Appoints Gilla Kaplan, Ph.D., to the Board of Directors

ROCKVILLE, Md. and CHESTERBROOK, Pa., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of...
September 10, 2020 07:00 ET | Source: Cerecor Inc.

Cerecor to Present at Upcoming Investor Conferences

ROCKVILLE, Md. and CHESTERBROOK, Pa., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of...
August 26, 2020 07:00 ET | Source: Cerecor Inc.

Cerecor Resumes Phase 1b Clinical Trial of CERC-002 for the Treatment of Severe Pediatric Onset Crohn’s Disease

ROCKVILLE, Md. and CHESTERBROOK, Pa., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ : CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of...
August 13, 2020 07:00 ET | Source: Cerecor Inc.

Cerecor Announces Peer-Reviewed Publication Highlighting the Role of the Inflammatory Cytokine, LIGHT, in COVID-19 ARDS

ROCKVILLE, Md. and CHESTERBROOK, Pa., Aug. 13, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ : CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of...
August 06, 2020 07:00 ET | Source: Cerecor Inc.

Cerecor Reports Second Quarter 2020 Financial Results and Business Update

-Generated net proceeds of $48 million from equity offering and disposition of Aytu shares to support pipeline advancement -Enrolled first patient in CERC-002 (anti-LIGHT mAb) clinical trial for the...
August 05, 2020 07:00 ET | Source: Cerecor Inc.

Cerecor to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference

ROCKVILLE, Md., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a leading biopharmaceutical company focused on the development and commercialization of treatments for rare pediatric...
August 04, 2020 07:00 ET | Source: Cerecor Inc.

Cerecor Receives Rare Pediatric Disease Designation for CERC-006 in Lymphatic Malformations

ROCKVILLE, Md. and CHESTERBROOK, Pa., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a leading biopharmaceutical company in the development and commercialization of treatments for...
August 03, 2020 07:00 ET | Source: Cerecor Inc.

Cerecor Receives Orphan Drug Designation for CERC-006 in Lymphatic Malformations

ROCKVILLE, Md. and CHESTERBROOK, Pa., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a leading biopharmaceutical company in the development and commercialization of treatments for...
July 21, 2020 07:00 ET | Source: Cerecor Inc.

Cerecor Announces First Patient Enrolled in Multicenter Proof-of-Concept Study Evaluating CERC-002 for COVID-19 ARDS

ROCKVILLE, Md., July 21, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for...
June 11, 2020 13:30 ET | Source: Cerecor Inc.

Cerecor Inc. Announces Closing of $37.95 Million Public Offering and Full Exercise of Underwriter’s Option to Purchase Additional Shares

ROCKVILLE, Md., June 11, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (Nasdaq: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare...